^
Association details:
Biomarker:No biomarker
Cancer:Endometrial Adenocarcinoma
Drug:ZN-c3 (WEE1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma

Published date:
11/17/2021
Excerpt:
Zentalis...today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ZN-c3, the Company’s oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma (USC) in adult women.